CHRS - Coherus Oncology, Inc.
NEXT EARNINGS:
Mar 9, 2026
(in 12 days)
EPS Est: $-0.31
|
Rev Est: $14.1M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.02
DETAILS
HIGH:
$11.00
LOW:
$1.05
MEDIAN:
$6.00
CONSENSUS:
$6.02
UPSIDE:
260.48%
Market Cap:
201.81M
Volume:
946,419
Avg Volume:
2,077,410
52 Week Range:
0.71-2.616
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.02
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
228
IPO Date:
2014-11-06
EPS (TTM):
0.25
P/E Ratio:
5.55
Revenue (TTM):
266.96M
Total Assets:
448.53M
Total Debt:
269.90M
Cash & Equiv:
125.99M
Rev Growth (5Y):
-5.6%
EPS Growth (5Y):
-28.0%
FCF Growth (5Y):
N/A
ROCE:
33.6%
Debt/Equity:
-2.04
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-0.33 | $-0.32 | -3.1% | $11.6M | $14.1M | -17.9% |
| 2025-08-07 | $-0.34 | $-0.31 | -9.7% | $10.3M | $12.0M | -14.5% |
| 2025-05-12 | $-0.35 | $-0.31 | -12.9% | $7.6M | $61.0M | -87.5% |
| 2025-03-10 | $-0.28 | $-0.10 | -180.0% | $54.1M | $60.0M | -9.8% |
| 2024-11-06 | $-0.01 | $-0.10 | +90.0% | $70.8M | $43.9M | +61.3% |
| 2024-08-08 | $-0.14 | $-0.21 | +33.3% | $65.0M | $61.4M | +5.9% |
| 2024-05-09 | $-0.32 | $-0.05 | -540.0% | $77.1M | $80.2M | -4.0% |
| 2024-03-13 | $-0.62 | $-0.21 | -195.2% | $91.5M | $96.4M | -5.1% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 266.96M | 257.24M | 211.04M | 326.55M | 475.82M | 356.07M | 1.56M | 1.56M | 190.11M | 30.04M | 31.11M | 2.75M |
| Net Income | 28.51M | (237.89M) | (291.75M) | (287.10M) | 132.24M | 89.83M | (209.34M) | (238.17M) | (127.34M) | (223.26M) | (87.13M) | (53.63M) |
| EPS | 0.25 | -2.53 | -3.76 | -3.81 | 1.85 | 1.29 | -3.22 | -4.48 | -3.04 | -6.01 | -10.64 | -2.97 |
| Total Assets | 448.53M | 629.60M | 480.85M | 679.33M | 841.65M | 408.93M | 99.47M | 162.61M | 178.49M | 212.38M | 187.22M | 47.45M |
| Total Debt | 269.90M | 480.84M | 480.42M | 419.02M | 417.10M | 188.64M | 103.09M | 101.41M | 100.26M | 0 | 0 | 4.20M |
| Cash & Equivalents | 125.99M | 102.89M | 63.55M | 417.19M | 541.16M | 177.67M | 72.36M | 126.91M | 124.95M | 158.23M | 150.39M | 39.55M |
| Operating Cash Flow | (20.44M) | (174.88M) | (241.12M) | (37.43M) | 154.15M | 28.36M | (159.27M) | (200.29M) | (252.54M) | (107.99M) | (23.93M) | 15.42M |
| Free Cash Flow | (20.44M) | (175.17M) | (243.16M) | (38.72M) | 146.91M | 15.46M | (160.06M) | (204.86M) | (259.06M) | (114.15M) | (26.78M) | 15.05M |
| FCF per Share | -0.18 | -1.86 | -3.13 | -0.51 | 2.06 | 0.22 | -2.46 | -3.86 | -6.18 | -3.08 | -3.27 | 0.83 |
| Book Value | (131.99M) | (193.43M) | (137.42M) | 97.73M | 280.97M | 105.21M | (38.59M) | 30.54M | 19.35M | (6.93M) | 66.76M | (42.38M) |
| Cash & ST Investments | 125.99M | 117.75M | 191.68M | 417.19M | 541.16M | 177.67M | 72.36M | 126.91M | 124.95M | 158.23M | 150.39M | 39.55M |
| ROC Equity | N/A | N/A | N/A | -2.94 | 0.47 | 0.85 | N/A | -7.80 | -6.58 | N/A | -1.31 | N/A |